KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 576.7 USD | +0.55% | +4.97% | +8.44% | 11.69% | ||
| 21.86 USD | +5.27% | -0.05% | -28.44% | 11.15% | ||
| 55.12 USD | +2.24% | -1.13% | -12.09% | 8.55% | ||
| 22.14 USD | +3.55% | -7.70% | -18.28% | 8.03% | ||
| 3.74 USD | +0.81% | -6.13% | -34.64% | 6.97% | ||
| 2.225 USD | +4.46% | +4.41% | -33.04% | 4.87% | ||
| 5.485 USD | +3.10% | -2.02% | -45.83% | 4.83% | ||
| 159.5 USD | -0.10% | -5.49% | +2.39% | 4.81% | ||
| 4.775 USD | +7.91% | +0.63% | -45.71% | 4.71% | ||
| 6.375 USD | +3.49% | -8.40% | -54.59% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
12/01/2022
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 31/10/2023 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
